ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the ...

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs). Design Using ...

Protein interactions play a crucial role in regulating cellular mechanisms, highlighting the need for effective methods to control these processes. In this regard, chemical inducers of proximity (CIPs ...

Avoid co-administration of XOLREMDI and strong CYP3A4 inducers. Reduce XOLREMDI daily dosage when administered with strong CYP3A4 inhibitors. Monitor more frequently for adverse reactions associated ...

Data supplied by Morningstar and accurate on Aug 19, 2024. It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of ...

Using genetic markers to adjust initial doses of cyclosporine or tacrolimus may prove difficult, considering the variety of polymorphisms known to affect CYP3A4, CYP3A5, and MDR1. The current ...

Both pharmacokinetic and pharmacodynamic differences can be observed among the different proton pump inhibitors (PPIs), which might influence their clinical application. Pharmacokinetic Properties ...

The Inspiring Learning Group owned 11 Kingswood camps, with Kingswood having been the largest programme provider for the National Citizen Service. Kingswood, whose history dates to the 1980s and ...